Liposphere presented its AqueousJoint knee joint injectable at the Alliance for Advanced Therapies in Orthopedics (ATiO, https://atioalliance.org/) conference in Berlin. Following competitive rounds of presentations, the Company won the Best Early-Stage Company award judged by a high-profile orthopedic audience and received the „Dancing Bear“ trophy.
where Biolubrication starts
Liposphere is a biomedical start-up spun out from the Weizmann Institute of Science (Israel) in early 2019. Its unique IP-protected platform technology of unmatched biolubricants has been developed over the past two decades at the Department of Materials & Interfaces under Professor Jacob Klein. Based on the profound knowledge of Klein and his team, Liposphere is now developing an innovative platform of highly lubricious, water-based biocompatible nanomaterials -named AqueousTech– for conditions in or in interaction with the human body where ultralow friction is crucial.
„Answering unmet medical needs“
There is an urgent, global, unmet medical need to develop innovative solutions, which can sustain forces within mechanically stressed environments. In the context of the human body, the major synovial joints such as the knee a or hip joint articulate under high-load conditions, whereas the cornea/eye lid interface for example is exposed to high shear stresses under low loads. Both scenarios when physiologically impaired are the exact pain points where Liposphere’s formulations can play a crucial role.
Liposphere’s formulation can be used as a pure lubricant, but also has the potential to encapsulate active pharmaceutical ingredients in the future, for delivery of pharmaceuticals to targets that currently are difficult to reach. In addition, Liposphere’s platform technology enables the coating of artificial medical surfaces such as catheters and protheses, giving the potential for smooth movement in a wide range of biomedical devices.
Introducing our unique product
The platform technology AqueousTech
Liposphere’s platform technology AqueousTech can be used as a pure lubricant to coat biological surfaces, but also provide the vehicle to encapsulate active pharmaceutical ingredients or supplements and to deliver these to targets that currently are difficult to reach.
In addition, Liposphere’s platform technology enables the robust coating of artificial medical surfaces such as catheters, hydrogels and needles, leading to ultra-low friction and improved lubrication when coated surfaces slide past each other in an aqueous system.
We develop AqueousJoint (Investigational Device) as an intra-articular injectable for the treatment of knee Osteoarthritis. AqueousJoint acts as a biocompatible, boundary lubricant coating the cartilage surfaces of the opposing bones of the knee joint, hence reducing friction and wear by providing superior lubrication.
// Reducing friction significantly by protecting cartilage
With the product line AqueousSurface (Investigational Device), Liposphere develops highly lubricious coatings for artificial surfaces relevant in different healthcare applications. Liposphere is currently conducting and establishing pilot studies with distinct commercial partners in the catheter and contact lens manufacturing sector.
// Coating artificial surfaces with ultra-low friction materials
News from Liposphere
The Israeli Ministry of Health approved our efficacy-focused clinical trial protocol. The trial will be a multi-center, double-blinded, and randomized study, and the primary outcome is to show the superiority of the AqueousJoint product compared to a saline solution (Placebo). Moreover, low, and high dosages of AqueousJoint will be used to identify the optimum product concentration.
Each group will recruit 50 patients to achieve statistically meaningful results.
The first clinical site in Assuta Hospital, Ashdod, was initiated. Further sites are Kaplan Hospital, Rehovot, Tel-Hashomer, Ramat-Gan, and Asaf Harofe Beer-Yacov, which will open soon to expedite recruitment.
20 Patients with diagnosed Osteoarthritis were enrolled in our First-In-Human safety trial in which the AqueousJoint product was clinically evaluated for the first time. Those patients received a single AqueousJoint injection into their knee joint cavity.
A follow-up time of 6 months was completed successfully, confirming the product’s safety (no related adverse events reported) and a long-lasting pain reduction effect of 6 months. The efficacy output was assessed using standardized questionnaires: The Knee Injury and Osteoarthritis Outcome Score (KOOS) and a Numeric Visual Scale (NVS) measure.
Follow us on LinkedIn
and stay connected
There is always exciting progress and news in our field of development and we are proud to be part of this dynamic process of shaping our future together. If you want to be part of this exciting journey and want to know today everything, that is new tomorrow, join us on LinkedIn!
Would you like to contact us? Call us or send us a message
using the contact form – looking forward to hearing from you.
Office: +972 (0) 732113227